Montana’s first Tendyne mitral valve replacement performed at Providence St. Patrick Hospital

May 10, 2022 Providence News Team

Providence St. Patrick Hospital’s International Heart Institute structural heart interventional team completed their first Tendyne procedure on May 3. Congratulations to Drs. Dan Spoon, Michael Reed, Todd Maddux and Joe Schmoker and their team for a successful first mitral valve interventional procedure in Missoula, Montana, once again! The patient is doing very well.

The Tendyne valve is a first-of-its-kind therapy to replace the mitral valve in patients in need of heart failure symptom relief and quality-of-life improvement without open heart surgery and when transcatheter mitral repair is not possible due to high surgical risk. This life-changing therapy treats significant mitral regurgitation in patients requiring a heart valve replacement.

As the most common heart disease affecting the heart valves, mitral regurgitation is a debilitating, progressive and life-threatening condition in which the heart's mitral valve does not close completely, allowing blood to flow backward into the left atrium of the heart.

For patients at high-risk for open-heart surgery or in clinical situations when the mitral valve is too damaged for a successful repair with the MitraClip device, the Tendyne offers a much-needed, alternative minimally invasive treatment option when the leaky valve needs to be replaced.

Global trial results to date have proven excellent procedural safety and have shown 98.9% of Tendyne patients experienced MR elimination at discharge which was sustained through one-year in this extremely sick patient group.

The self-expanding valve is delivered through a small incision in the chest and up through the heart where it is implanted in a beating heart, replacing the person's native mitral valve. The Tendyne valve is available in multiple sizes to treat a broad range of valve anatomies.

The Tendyne is an investigational device in the U.S. The International Heart Institute is only one of 74 places in the U.S. that are part of this life-saving research This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne valve compared to the MitraClip in patients with symptomatic, moderate-to-severe, or severe mitral regurgitation.

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Welcome to your journey for creating a healthier you

Montana’s first Tendyne mitral valve replacement performed at Providence St. Patrick Hospital

About the Author

Previous Article

Next Article

Montana’s first Tendyne mitral valve replacement performed at Providence St. Patrick Hospital

About the Author

Previous Article

Next Article

Other content in this Stream

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Learn about dysautonomia, its symptoms, and how it's connected to long COVID. Discover treatment options and expert insights at Providence.

A research collaboration between CORE, PSU researcher Dr. Roberta Hunte and the Healthy Birth Initiative (HBI), is studying the impact of a cross-sector partnership on Black maternal health outcomes.

A novel peptide vaccine against glioblastoma, a deadly brain tumor, is offering hope to some patients thanks to the work of an international effort including Providence's Santosh Kesari, MD, PhD.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

The procedure using the new TriClip to repair a leaky tricuspid valve was also a first in the Pacific Northwest.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A first-of-its-kind study on the efficacy and safety of weight loss medications in the real world is helping to provide clinicians with new is helping to provide clinicians with valuable new evidence.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

Over the next three years, this study seeks to identify the patterns of access and use of cancer services among high-risk patients to understand how to guide them toward quality care.

Providence researchers conducted over 2400 studies in 2023, according to the 2023 Providence Research Network Annual Report

Learn more about a clinical trial for men with metastatic prostate cancer.

In North Puget Sound, Providence Swedish has implemented solutions to address opioid overdoes, including participating in grant programs and research to discover addiction treatments that work.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

The largest study of angiosarcoma published to date, co-authored at Providence, describes the incidence and presentation patterns of angiosarcoma, a rare but potentially deadly cancer.

The 2023 Providence Research Network annual report, released on Clinical Trials Day 2024, highlights the breadth and impact of research at Providence.